In the second part of our exclusive interview with GSK Consumer Healthcare's EMEA Head Filippo Lanzi, we find out more about GSK’s new mission-oriented strategy, for example how its household European OTC brands like Dr Best and Alvedon are already going green. Widening access to medicines via Rx-to-OTC switch is also still a priority, Lanzi says, as well as exciting new trends in the region’s wellness market such as CBD.
Since becoming the largest OTC company in the world through its joint venture with Pfizer, GSK Consumer Healthcare is on a mission to make the post-COVID world a better place.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.
Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.
Speaking at a recent AESGP webinar, sustainability expert Onur Durmus called the the European Commission’s “Omnibus” proposals - designed to simplify ESG reporting rules and recently supported by EU Parliament - a “positive development” for the European consumer health industry.
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.
